Disruptive Cardiology VectraCor offers a patented Cardiac Electrical Biomarker and a multi-lead ECG capability that can enhance existing cardiac monitors. This presents a compelling upsell opportunity to healthcare providers seeking earlier AMI detection and more comprehensive monitoring without adding multiple separate devices.

AM I Detection The real-time VectraplexAMI index and alarm could be marketed to emergency departments, hospitals, and EMS agencies as a differentiator for early AMI detection, enabling faster triage and potential reduction in time-to-treatment.

All-in-One Monitoring The system derives 15-lead ECG in the US (and 22-lead in the EU) from a 5-electrode setup, offering a simpler workflow and potential cost savings for facilities. This can appeal to cardiology groups, ICU, and perioperative teams seeking streamlined monitoring.

Clinical Footprint With worldwide patents and multiple published papers, the product has research credibility that can support partnerships, clinical trials, and pilot programs with larger medical device distributors and hospital networks.

Strategic Partnerships As parent company of QRS Diagnostics, VectraCor can leverage existing distribution channels for ECG and spirometry devices to accelerate market entry, cross-sell to current customers, and expand reach into emergent markets.